112088-77-4

Basic information

• Product Name: 6-chloro-9-(4-methoxybenzyl)-9H-purine
• Synonyms: 6-chloro-9-(4-methoxybenzyl)-9H-purine
• CAS NO: 112088-77-4
• Molecular Formula: C₁₃H₁₁ClN₄O
• Molecular Weight: 274.70564
• Mol File: 112088-77-4.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-chloro-9-(4-methoxybenzyl)-9H-purine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-9-(4-methoxybenzyl)-9H-purine(112088-77-4)
• EPA Substance Registry System: 6-chloro-9-(4-methoxybenzyl)-9H-purine(112088-77-4)

Safety Data

• Hazardous Substances Data: 112088-77-4(Hazardous Substances Data)

Usage

Chemical compound

6-chloro-9-(4-methoxybenzyl)-9H-purine

Family

Purine

Type

Purine analog and kinase inhibitor

Therapeutic potential

Treatment of cancer and viral infections

Mechanism of action

Blocks growth and proliferation of cancer cells by inhibiting signaling pathways

Antiviral activity

Demonstrated against certain viruses

Current status

Under investigation for potential uses, further research needed

Upstream product

• 2746-25-0 p-Methoxybenzyl bromide 
• 87-42-3 6-chloropurine 
• 87-42-3 6-chloro-7H-purine 
• 824-94-2 p-methoxybenzyl chloride 

Downstream Products

• 1125-39-9 1-Methylhypoxanthine 

Relevant articles and documents

OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS

The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1, R4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Synthesis, biological activity, and SAR of antimycobacterial 9-aryl-, 9-arylsulfonyl-, and 9-benzyl-6-(2-furyl)purines

9-Aryl-, 9-arylsulfonyl- and 9-benzyl-6-(2-furyl)purines were synthesized by N-alkylation or N-arylation of the purine followed by Stille coupling to introduce the furyl substituent in the 6-position and the compounds screened for activity against Mycobac